GLOW Peptide Dosage in the Research Literature

GLOW peptide dosage as studied in the literature varies substantially by constituent, species, route, and study type. The figures below are from published preclinical and clinical research; they are not equivalent to a human dosing protocol.

GHK-Cu: In vitro fibroblast and gene-expression studies used concentrations of 1–10 nM ^[2]. Clinical trials for topical skin applications used cream and nano-carrier formulations ranging from 0.05% to 0.1–10 micromolar, applied twice daily for 8–12 weeks [4, 5]. An intradermal injection study for hair follicle stimulation used a GHK-Cu formulation at an unspecified concentration, documenting visible growth indicators within 10 days ^[8]. Subcutaneous injection into wound chambers used sequential injections in rodent models at concentrations not specified in reviewed abstracts ^[24].

BPC-157: Rodent wound and tissue repair models used 10 µg/kg, 10 ng/kg, and 10 pg/kg body weight — demonstrating consistent efficacy across a three-log dose range ^[13]. In vitro fibroblast studies used 0.1–0.5 µg/mL ^[14]. Topical cream formulations in burn models used 1 µg/g of cream ^[11]. CNS and stroke studies used 1 ng/kg to 10 µg/kg via intraperitoneal or intragastric routes ^[15].

TB-500 (Thymosin Beta-4): Keratinocyte migration was stimulated in vitro at concentrations as low as 10 picograms ^[17]. Rodent topical application studies used unspecified concentrations that doubled follicle growth within 7 days ^[19]. Phase 2 human wound trials used the full-length Tβ4 protein at doses not specified in retrieved abstracts ^[20].

Clinic-sourced protocols (not from controlled published trials) describe the GLOW blend as: BPC-157 at 250–500 µg daily, GHK-Cu at 2 mg daily, and TB-500 at 1–2 mg 2–3x weekly via subcutaneous injection. These are observational clinic figures, not RCT-validated parameters. See the BPC-157 skin healing research section for the preclinical pharmacology context.

BPC-157: The most characterized of the three constituents. Elimination half-life under 30 minutes in both rats and dogs (IV). Intramuscular bioavailability 14–19% in rats and 45–51% in dogs. Rapidly metabolized to amino acid fragments via urinary and biliary excretion (15.88% recovery at 72 hours in rat urine) ^[16]. Linear pharmacokinetics. The short plasma residence in animal models provides the research rationale for daily administration schedules — plasma concentration returns to near-zero within hours of a single dose.

GHK-Cu: An endogenous peptide with no published systemic pharmacokinetic study for injectable formulations. Topical formulations require adequate delivery vehicles to cross the stratum corneum — liposomal encapsulation and palmitoylation have been studied as strategies. A 2025 Molecules study identified a methodological gap in measuring liposomal GHK-Cu skin permeation: standard assays measure free-form peptide only, potentially underestimating intact-liposome delivery ^[10].

TB-500: Thymosin Beta-4 is a naturally occurring intracellular protein; specific pharmacokinetic data for the TB-500 synthetic fragment have not been retrieved in published form. Reconstituted TB-500 stored at 4°C in bacteriostatic water is reported stable for 14–28 days in industry references; no peer-reviewed stability data was identified.

Routes of administration studied in the published literature differ by constituent:

GHK-Cu has been studied via topical cream/serum/nano-carrier, intradermal injection (hair follicle studies), and subcutaneous injection into wound chambers in rodent models [8, 24]. Systemic injectable routes in humans have not been studied in controlled trials.

BPC-157 has been studied via intraperitoneal injection, oral gavage/drinking water, topical cream, subcutaneous injection, and intragastric administration in animal models ^[13]. No injectable human clinical trial data exists beyond the three small pilot studies ^[22].

TB-500 (Thymosin Beta-4) has been studied via topical application and intraperitoneal injection in animal models, and systemically in Phase 2 human wound trials (specific route not detailed in retrieved abstracts) ^[20].

Clinic protocols describe subcutaneous injection into abdominal fatty tissue as the administration route for the GLOW blend. Site-specific absorption differences have not been formally quantified for any of the three constituents in the injectable injectable context.

Clinic-sourced literature describes 4-week active cycles followed by 2-week rest periods to reduce receptor accommodation. No controlled cycling study exists for any individual constituent or for the GLOW blend. The 4-week-on/2-week-off pattern is an observational clinic convention — not a parameter validated in any published trial [22, 23].

The absence of cycling data is notable against the preclinical record: animal wound-healing studies use acute or short-course administration models (days to weeks), not long-term cycling paradigms. The long-term continuous administration of any constituent has not been studied in controlled trials.

Published clinic protocols cap continuous use at 4–6 weeks before a rest period. Long-term continuous administration has not been studied in any controlled trial for BPC-157, TB-500, or the GLOW blend [22, 23]. GHK-Cu topical trials extended to 12 weeks without a documented rest period, but these are topical applications, not injectable protocols.

Animal studies for BPC-157 used single-dose or multi-day administration schedules; the short plasma half-life (under 30 minutes IV in rats and dogs ^[16]) provides the mechanistic rationale for daily injection in research contexts. GHK-Cu clinical trials used twice-daily topical application. TB-500 animal studies used topical or intraperitoneal administration without standardized frequency reporting. Clinic protocols describe daily subcutaneous injection for BPC-157 and GHK-Cu components, with TB-500 dosed 2–3 times weekly. These schedules reflect observational clinic practice, not controlled trial parameters.

Clinic protocols describe BPC-157 at 250–500 µg daily, GHK-Cu at 2 mg daily, and TB-500 at 1–2 mg 2–3x weekly. These are observational clinic figures drawn from clinic-sourced documentation, not from any published randomized controlled trial. Published animal research doses (BPC-157 at 10 µg-10 pg/kg bodyweight; GHK-Cu at 1–10 nM in vitro) do not translate directly to human mg doses [13, 16]. The TB-500 tissue repair studies page notes that Phase 2 human Thymosin Beta-4 trials did not report specific dose parameters in retrieved abstracts.

Clinic documentation describes reconstitution with bacteriostatic water — typically 3 mL for a standard 70 mg GLOW vial — yielding approximately 23 mg/mL total peptide concentration for dosing calculations. This is a clinic-protocol convention; no peer-reviewed publication has validated this specific reconstitution parameter or assessed stability of the reconstituted three-component blend. BPC-157 is stable in gastric acid for more than 24 hours, supporting aqueous reconstitution, but injectable stability data for the blend is not available in the published literature.

Clinic documentation describes 3 mL of bacteriostatic water for a standard 70 mg GLOW vial; this yields approximately 23 mg/mL total peptide concentration for dosing calculations. No peer-reviewed protocol validates this specific reconstitution figure or the stability of the resulting blend solution.

Subcutaneous injection into abdominal fatty tissue is the site most frequently described in clinic-based protocols. Site-specific absorption differences have not been formally quantified for any of the three GLOW constituents in the injectable context. BPC-157 animal studies used intraperitoneal (not subcutaneous) injection for most systemic models ^[13]; direct subcutaneous data for BPC-157 or TB-500 in humans is not available in controlled trial form.

Subcutaneous (under-skin) injection into abdominal fatty tissue is the most frequently described site in clinic-based protocols. Variable individual absorption across injection sites is noted in clinic reports. No published human study has compared absorption rates across injection sites for the GLOW blend or its individual constituents. The reconstitution and injection protocol section covers preparation conventions in detail.

Published clinic protocols cap continuous use at 4–6 weeks before a rest period. Longer uninterrupted courses have not been studied in any controlled trial. The 4-week-on/2-week-off convention is an observational practice pattern, not an RCT-validated safety or efficacy parameter [22, 23].